Skip to main content

Table 3 SUCRA values for four outcomes

From: Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis

OS

PFS

SAEs

RP

Treatment

SUCRA

Treatment

SUCRA

Treatment

SUCRA

Treatment

SUCRA

SP

0.80

PP

0.89

UP

0.03

MVP

0.32

PP

0.70

PP-Cet

0.86

SP

0.11

PP

0.36

PP-Cet

0.68

EP

0.75

PP

0.33

PP-Cet

0.37

UP

0.68

UP

0.74

PP-Cet

0.38

NP

0.41

NP

0.65

DP

0.55

PC

0.41

UP

0.42

EP

0.60

SP

0.48

NP

0.50

DP

0.46

DP

0.60

NP

0.41

EP

0.50

EP

0.47

MVP

0.35

PC-Cet

0.36

GP

0.60

GP

0.47

PC

0.29

PC

0.35

PC-Cet

0.69

SP

0.50

IC

0.28

MVP

0.28

IC

0.7

IC

0.69

PC-Cet

0.22

IC

0.17

DP

0.75

PC

0.69

GP

0.15

GP

0.15

MVP

1.0

PC-Cet

0.83

  1. Abbreviations: OS overall survival, PFS progression-free survival, SAE serious adverse events, RP radiation pneumonitis, SUCRA surface under the cumulative ranking curve, EP etoposide-cisplatin, PC paclitaxel-cisplatin/carboplatin, UP uracil/tegafur(UFT)-cisplatin, NP vinorelbine-cisplatin, PP pemetrexed-cisplatin/carboplatin, SP S-1-cisplatin, DP docetaxel-cisplatin, GP gemcitabine-cisplatin, MVP mitomycin-vindesine-cisplatin, IC irinotecan-carboplatin, Cet cetuximab
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us